Search

Background: Cardiotoxicity of aggressive chemotherapeutic regimens includes cardiomyopathy and arrhythmias. Although cardiomyopathy is a well-recognized entity, arrhythmias are poorly studied., Hypothesis: Certain chemotherapeutic regimes are associated with supraventricular arrhythmias, particularly atrial fibrillation., Methods: We retrospectively reviewed the data on patients who received hematopoietic stem cell transplant (bone marrow transplant; BMT) from 1998 to 2005 and developed supraventricular tachycardia (SVT) during the same hospital admission. The Fisher χ2 test and the Student t test were used for comparison of categorical and continuous variables, respectively., Results: During the period of 1998-2005, there were 1221 BMTs, 62 (5.1%) of which were complicated by SVT. Melphalan-based regimens demonstrated a significantly higher rate of SVT than any other chemotherapy. Out of 438 patients who received melphalan, 48 (11%) developed atrial fibrillation (n = 35) or SVT (n = 13) during the same hospital admission, and 390 did not. Patients with SVT were older, had higher baseline creatinine, larger size of the left atrium, and more cardiac comorbidities. Incidence of SVT was associated with greater length of stay (24.9 ± 8.9 d vs 19.6 ± 5.8 days, P<0.0001), even after adjustment for comorbidities., Conclusions: Supraventricular tachycardia, mostly atrial fibrillation, complicates about 5% of chemotherapeutic treatments used with BMT. Melphalan is the most arrhythmogenic agent, and is associated with SVT in 11% of patients. Development of SVT results in about a 4-day increase in the length of hospital stay., (© 2011 Wiley Periodicals, Inc.)

Background: The AFFIRM trial demonstrated no mortality benefit from a rhythm control strategy compared with rate control of atrial fibrillation (AF). However, AF is associated with greater morbidity and mortality and poorer functional status than sinus rhythm, which is more likely to be achieved with a rhythm control strategy., Objective: This study sought to compare heart failure (HF) symptoms in the different AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) subgroups depending on the prevalence of AF or sinus rhythm throughout the follow-up period., Methods: This study analyzed a limited-access dataset from the AFFIRM trial, provided by the National Heart, Lung, and Blood Institute., Results: Symptomatic HF was more common in the rate control than in the rhythm control arm. On analysis based on actual rhythm, New York Heart Association functional status was the best in patients who were in stable sinus rhythm, worse if they were consistently in AF, and much worse if they were changed back and forth between the rhythm control and rate control strategies. Patients in all groups had fewer HF symptoms and required less HF medications when they were in sinus rhythm compared with AF, except for those who crossed over from the rhythm to the rate control strategy., Conclusion: Patients in the rhythm control arm had fewer HF symptoms than those in the rate control arm. Stable sinus rhythm was associated with the best functional status. Patients who are the most symptomatic in AF but are unable to maintain normal sinus rhythm if treated by the means used in the AFFIRM trial may be candidates for other treatment options, such as ablation., (Copyright 2010 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.)